Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTH258 vs aflibercept in neovascular AMD (China)
CTR20191975Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of brolucizumab in exudative macular degeneration, sponsored by Novartis. Started Oct 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20191975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191975.